DUBLIN–(BUSINESS WIRE)–The “Biosensors Market: Focus on Drug Discovery and Development – Distribution by Biosensor Type, End-User Type, and Key Geographies – Industry Trends and Global Forecast, 2022-2035” report has been added to from ResearchAndMarkets.com offer.

Currently, various types of biosensors including optical biosensors, electrochemical biosensors, thermal biosensors and others are deployed at different stages of drug discovery, such as disease modeling, identification/validation of targets, lead identification, lead optimization and other applications.

The use of biosensing technologies in drug discovery operations is expected to improve overall R&D productivity by enabling accurate screening and identification of key drug compounds. Currently, more than 80 biosensors are commercially available/under development by various industry players for drug discovery and development purposes.

In addition, more than $1.2 billion has been invested in this market by private and public sector investors over the past five years. Interestingly, almost 50% of the aforementioned amount has been invested in the last two years, reflecting the growing interest of stakeholders in this area.

It should also be noted that more than 370 patents related to biosensors in drug discovery have been filed/granted, highlighting the continued pace of innovation in this field. Considering the active initiatives undertaken by the players in this field, we are led to believe that the opportunity for the players in this niche but to come, the industry is likely to grow at a commendable rate for the foreseeable future.

Report scope

The “Biosensors Market: Focus on Drug Discovery and Development – Breakdown by type of biosensor (optical, electrochemical, thermal and others), type of end-user (academic and research institutes and industrial players) and key geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2035” report presents an in-depth study of the current market landscape and future potential biosensors in drug discovery, over the next 13 years. The study presents an in-depth analysis of the main drivers and trends related to this field. Among other elements, the report includes:

• A detailed assessment of the current Biosensors in Drug Discovery market landscape, along with insights into several relevant parameters.

• An analysis of the competitiveness of biosensor products used for drug discovery purposes.

• An analysis of investments that have been made in companies developing biosensors for drug discovery applications, including seed funding, venture capital funding, capital raised in IPOs and subsequent offerings, grants and debt financing.

• A detailed review of over 333 peer-reviewed scientific papers related to biosensor research in drug discovery.

• A detailed analysis of the global events attended by participants, based on several relevant parameters, such as the year of the event, the type of event platform, the location of the event, the domains of interest, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants and affiliated organizations of the participant. The chapter also highlights the geographic mapping of upcoming events.

• An in-depth analysis of various patents filed/granted related to biosensors in drug discovery.

Main topics covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. PRESENTATION

4. MARKET LANDSCAPE

5. PRODUCT COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES: DEVELOPERS OF BIOSENSORS FOR DRUG DISCOVERY APPLICATIONS

7. BRAND POSITIONING ANALYSIS

8. FINANCING AND INVESTMENT ANALYSIS

9. ANALYSIS OF PUBLICATIONS

10. ANALYSIS OF GLOBAL EVENTS

11. PATENT ANALYSIS

12. MARKET FORECASTS AND OPPORTUNITY ANALYSIS

13. CONCLUSIONS

14. MANAGEMENT OVERVIEW

Companies cited

• 3E Bioventures Capital

• ACEA Biosciences

• Agency for Science, Technology and Research (A*STAR)

• AgilentTechnologies

• Agilome

• Alexandria Venture Investments

• Applied biophysics

• Aromyx

• ARTIS Ventures

• Attana

• Axion BioSystems

• Ballast point companies

• Therapeutic Beactica

• BioLoomics

• BioNavigations

• BiOptix Analytics

• Biosens Laboratories

• Biodetection instrument

• Boston University

• Brucker

• Cardea Organic

• cartera

• Catalan Institute of Nanosciences and Nanotechnologies (ICN2)

• chinese academy of sciences

• Technology and Life Sciences Division of Comerica Bank

• Colombia University

• Efferent Laboratories

• Eindhoven University of Technology

• Falcon III Ventures

• Garage Capital

• Organic alligator

• GE Healthcare

• Genapsys

• Harvard College

• IBM

• Indian Institute of Technology, Madras

• InterAx Biotech

• International Iberian Nanotechnology Laboratory (INL)

• Interuniversity Microelectronics Center (IMEC)

• Invitrometrix

• Karlsruhe Institute of Technology

• Laurier Seed Fund

• Lifetime investments

• lino Biotech

• MagArray

• Malvern analysis

• MaRS Investment Accelerator Fund

• Micro-vacuum cleaner

• Molecular devices

• Monash University

• Montana Molecular

• National Center for Scientific Research (CNRS)

• National Institute on Drug Abuse

• National Nanotechnology Coordination Office (NNCO)

• Nicoya Life Sciences

• Ningbo University

• NRI R&D patent licenses

• OMX Ventures

• Osaka University

• University of Chicago

• Johns Hopkins University

• University of Malaysia

• Craiova University of Medicine and Pharmacy

• University of Minnesota

• Montreal university

• University of Oxford

• University of Porto

• University of Strathclyde

• Vanderbilt University

• University of Waterloo Student Venture Fund

• Warsaw University of Technology

• water company

• Whitecap Venture Partners

For more information on this report, visit https://www.researchandmarkets.com/r/6uoe4w